Lupin voluntarily recalls anti-infectious drug from US market
- Essar Leaks: SC issues notices to Essar Group and Centre on PIL seeking court-monitored probe
- Karnataka CM announces CBI probe into death of IAS officer DK Ravi
- Hashimpura massacre: 10 freed still in UP Police
- Jaitley, Rajan paper over the cracks, minister says in regular, frank talks
- Lee Kuan Yew, founder of modern Singapore, passes away at 91
Pharma major Lupin is voluntarily recalling some lots of Suprax, which is used to treat common infections, from the US market on account of discolouration, according to US Food and Drug Administration (USFDA).
The nationwide recall has been initiated by the company on January, 31 this year.
The recall of 64,368 bottles of Suprax (cefixime for oral suspension) was initiated under Class-III which FDA defines as a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
"Discoloration; Product may not meet specifications for color description once reconstituted," the USFDA notification said on the reasons for the Lupin recall.
Financial and other implications of the recall could not be ascertained as an email sent to the company seeking comments remained unanswered.
Suprax contains cefixime, which is a third-generation oral cephalosporin that has an important role in treating common infections.
Lupin shares closed 0.89 per cent down at Rs 684.70 apiece on BSE.